Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Discovery announces multi-target drug discovery deal with Sitryx Therapeutics

Sitryx Therapeutics selects Sygnature Discovery for multi-target, integrated drug discovery collaboration.

The energetic status of cells has been shown to be pivotal in controlling the behaviour of disease associated cells in immuno-oncology and immuno-inflammation.  Correcting immune cell function and/or inhibiting tumour cell growth through targeting metabolic pathways has the potential to deliver new complementary and highly-differentiated approaches to treat a wide range of severe diseases.

Sitryx’s proprietary science is led by a highly-experienced management team, supported by GlaxoSmithKline‘s drug discovery experience and world-class academic founders, in addition to Sygnature’s significant expertise in immuno-oncology and immunology drug discovery.  Sitryx Therapeutics was founded by six world-leading researchers in the field of immunology and immuno-regulation, including Houman Ashrafian, Luke O’Neill, Jonathan Powell, Jeff Rathmell, Michael Rosenblum and Paul Peter Tak.

Commenting on the collaboration, Sygnature’s CEO and Founder, Dr Simon Hirst said: “We are pleased to have been selected by Sitryx to support their ground-breaking research efforts to develop disease-modifying therapeutics across multiple biological targets in immuno-oncology and immuno-inflammation.  Our considerable in-house knowledge of immuno-oncology and immunology discovery will enable us to efficiently navigate these complex areas of biology to support the identification and optimisation of novel and selective small molecules while developing a deep understanding of their mode-of-action.”

Dr Neil Weir, Sitryx’s CEO, said, “Sygnature Discovery has an established reputation as a provider of premium integrated drug discovery and pre-clinical services and the Sitryx team has an extensive track record of success in the discovery and development of novel drugs.  We will combine our considerable know-how and expertise to deliver new, highly-effective disease-modifying therapeutics in immuno-oncology and immuno-inflammation.”

To find out more, please contact 0115 941 5401.

Latest News

View All

Sygnature Discovery announces multi-target drug discovery deal…

Dr. Scott Pollack – IDO Inhibitors and…

Dr. Scott Pollack – Intracellular Enzyme Inhibitors…

Dr. Scott Pollack – Ensuring Strong Hit-to-Lead…

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.